secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001493152-24-009063
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem amends merger with Aditxt; extends proxy deadline, equity investment replaces loan
--------------------------------------------------------------------------------

- Third Amendment extends joint proxy statement filing deadline to April 30, 2024.
- Aditxt replaces $3.5M Parent Loan with equity purchases: $2M by Apr 1, $1.5M by Apr 30 in Series F-1 Preferred.
- Aditxt assigns notes back to holders; Jan 2024 Secured Notes maturity extended to Mar 31, 2024; balance reduced to $250k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224009063/0001493152-24-009063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224009063/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer